ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1043

A Prospective Study on Early Diagnosis of Inflammatory Rheumatic Diseases Using an Enhanced Online Questionnaire System (RhePort 1.3)

Cay von Der Decken1, Stefan Kleinert2, Matthias Englbrecht3, Kirsten Karberg4, Georg Gauler5, Susanna Spaethling-Mestekemper6, Christoph Kuhn7, Wolfgang Vorbrueggen8, Martin Welcker9 and Peter Bartz-Bazzanella10, 1Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, 2Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, 3Freelance Healthcare Data Scientist, Eckental, 4Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, 5rheumapraxis, Osnabrück, Germany, 6Rheumapraxis Muenchen, Muenchen, Germany, 7Praxis für Rheumatologie, Karlsruhe, Germany, 8Verein zur Foerderung der Rheumatologie e.V, Wuerselen, Germany, 9Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, 10Rhein-Maas Klinikum, Wuerselen, Germany

Meeting: ACR Convergence 2024

Keywords: , ,

Session Information

Date: Sunday, November 17, 2024

Title: Health Services Research – ACR/ARP Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The RhePort system, accessible via “www.RhePort.de” and featuring an integrated questionnaire with a specialized algorithm, aims to facilitate the early diagnosis of inflammatory rheumatic diseases (IRD). This system prioritizes access for primary care physicians and patients to a first consultation with a rheumatologist, enabling earlier diagnosis and quicker initiation of specific therapies, such as DMARDs and biologics. This project evaluates the upgraded version, RhePort 1.3, using a newly designed questionnaire and assesses its performance.

Methods: This prospective study included patients completing the RhePort questionnaire online or during their first rheumatological appointment. The RhePort system generated a score based on the responses, which was followed by a rheumatological consultation to confirm or exclude inflammatory IRD. The largest subgroups of patients diagnosed with IRDs (20 patients each at least) were analyzed regarding their mean RhePort score compared to the group of patients  also referred to participating study centers but ultimately diagnosed not having IRD.

Results: Among 614 diagnoses (table 1), no rheumatic disease was found in 63.4%. Patients with no inflammatory rheumatic disease (IRD) had a mean RhePort score of 1.42 (95% CI: 1.30-1.55). Higher mean scores were seen in those diagnosed with rheumatoid arthritis (RA) [2.15 (95% CI: 1.87-2.43)] and polymyalgia rheumatica (PMR) [2.12 (95% CI: 1.55-2.69)]. Corresponding effect sizes compared to patients without IRD (moderate effect: d > 0.5) are displayed in figure 1. Axial spondyloarthritis (axSpA) had a mean score of 2.07 (95% CI: 1.40-2.75), and patients with psoriatic arthritis (PsA) of 1.74 (95% CI: 1.41-2.08). See table 2 for further details.

Conclusion: The upgraded RhePort 1.3 system, significantly aids in detecting patients with (IRD), ensuring quicker access to appropriate rheumatological care and facilitating timely intervention. The RhePort system’s potential for broader application in clinical practice warrants further investigation to optimize its diagnostic algorithms and expand its use in diverse healthcare settings.

Supporting image 1

Table 1: Complete Diagnoses, n = 614

Supporting image 2

Figure 1: Average RhePORT Score. Effect Sizes RA, PsA, PMR, and axSPA compared to no IRD.

Supporting image 3

Table 2: Diagnoses groups for analyzes, n = 566 with mean RhePORT Score, Age, Sex.

Disclosures: C. von Der Decken: AbbVie/Abbott, 12, Versorungssymposium 2024, Galapagos/Alphasigma, 12, DGRh-Kongress 2023 and 2024; S. Kleinert: AbbVie/Abbott, 6, Chugai, 6, Novartis, 5, 6; M. Englbrecht: AbbVie, 2, Sanofi, 6; K. Karberg: None; G. Gauler: AbbVie/Abbott, 6, Eli Lilly, 1, Novartis, 6, UCB, 6; S. Spaethling-Mestekemper: AbbVie/Abbott, 6, Boehringer-Ingelheim, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, Novartis, 6, UCB, 6; C. Kuhn: None; W. Vorbrueggen: None; M. Welcker: AbbVie/Abbott, 1, 5, 6, Boehringer-Ingelheim, 1, 5, 6, Eli Lilly, 1, 6, Gilead, 1, 6, Novartis, 1, 5, 6; P. Bartz-Bazzanella: AbbVie/Abbott, 6, Boehringer-Ingelheim, 6, Eli Lilly, 6, Novartis, 5, 6.

To cite this abstract in AMA style:

von Der Decken C, Kleinert S, Englbrecht M, Karberg K, Gauler G, Spaethling-Mestekemper S, Kuhn C, Vorbrueggen W, Welcker M, Bartz-Bazzanella P. A Prospective Study on Early Diagnosis of Inflammatory Rheumatic Diseases Using an Enhanced Online Questionnaire System (RhePort 1.3) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/a-prospective-study-on-early-diagnosis-of-inflammatory-rheumatic-diseases-using-an-enhanced-online-questionnaire-system-rheport-1-3/. Accessed .

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-prospective-study-on-early-diagnosis-of-inflammatory-rheumatic-diseases-using-an-enhanced-online-questionnaire-system-rheport-1-3/